Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (706)	2/19/1998 1:01:00 PM
From: seminole	Respond to of 1826

Peter <<< It's conceivable that it works better (or at least very differently) in the mdr-tumors than in non-mdr-tumors. If so, how do you design Phase II's to pick this up?>>>> If this was true (I don't think it is), not being a doctor, having occasionally looked through Seminars in Oncology, and willing to spend the money from Salagen; I would cocktail hydroxymethylacylfulvene with another drug. I would get ready for a second Phase II or second Phase III trial with the current trendy drug combo application. I would select the other drug based on which drug gave the best synergy. Goodbye Harry, Cubs Win, Cubs win richard